原发性胆汁性胆管炎的治疗进展  

Research advances in treatment of primary biliary cholangitis

作　　者：李艳梅[1] 王绮夏[1] 马雄[1] 

机构地区：[1]上海交通大学医学院附属仁济医院消化内科,上海市消化疾病研究所,上海200001

出　　处：《临床肝胆病杂志》2016年第8期1491-1496,共6页Journal of Clinical Hepatology

摘　　要：原发性胆汁性胆管炎是一种主要累及肝内小叶间胆管的自身免疫性肝脏疾病,可发展至肝纤维化、肝硬化甚至肝衰竭。目前熊去氧胆酸(UDCA)是唯一被批准的治疗用药,但仍有高达40%的患者对UDCA应答不佳,发生相关并发症的风险增加。目前,其他药物及治疗方法如:贝特类药物、糖皮质激素、免疫抑制剂、奥贝胆酸、生物制剂及间充质干细胞已逐步开展临床应用,为治疗此类患者带来希望。Primary biliary cholangitis（ PBC） is an autoimmune liver disease mainly involving intrahepatic interlobular bile ducts and can progress to liver fibrosis,cirrhosis,and even liver failure. At present,the only drug approved for the treatment of PBC is ursodeoxycholic acid（ UDCA）,but up to 40% of PBC patients have suboptimal response to UDCA,and the risk of related complications is increased. Nowadays,other drugs and treatment methods,such as fibrates,glucocorticoids,immunosuppressants,obeticholic acid,biological agents,and mesenchymal stem cells,have been gradually applied in clinical practice and have brought the hope for the treatment of these patients.

关 键 词：肝硬化 胆汁性 熊脱氧胆酸 治疗 

分 类 号：R575.7[医药卫生—消化系统]